Biocompatibles International plc was a medical technology company in the field of drug-device combination products. It was acquired by BTG plc in 2010,[2] which was, in turn, acquired by Boston Scientific in 2019.[3][4]
Approved oncology products were supplied and marketed from facilities in Farnham, Surrey, UK and Oxford, Connecticut.
Products included drug-eluting bead products that are used in more than 35 countries for the treatment of primary liver cancer (HCC), liver metastases from colorectal cancer and other cancers. The company supplied and marketed brachytherapy products (radiation-delivering seeds) that are used to treat prostate cancer.[5]
Its UK research and development facilities were engaged in licensing and in new product development based on the company's core drug delivery technologies in the treatment of cancers.